- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on PD1
Total 265 results
-
Xiaohua ZhuRecruitingNSCLC Stage IV | PD-L1 Gene AmplificationChina
-
The First Hospital of Jilin UniversityRecruitingPD-L1 Positive Locally Advanced Patients With Resectable Gastric CancerChina
-
Fuzhou General HospitalUnknownSmall Cell Lung Cancer | Lung Neoplasm | PD-1 InhibitorsChina
-
West China HospitalRecruitingBRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal AntibodyChina
-
Radboud University Medical CenterCompletedParoxysmal Nocturnal Hemoglobinuria | Eculizumab | PK-PDNetherlands
-
AbbVieCompletedParkinson's Disease (PD)United States, Finland, Greece, Hungary, Italy, Slovakia, Spain
-
Tel-Aviv Sourasky Medical CenterUnknownWhite Matter Lesions | Postural Instability Gait DisordersIsrael
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingRecurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
-
Adamas Pharmaceuticals, Inc.CompletedParkinson's Disease (PD) | Dyskinesia | Levodopa-Induced Dyskinesia (LID)France, Spain, United States, Germany, Austria
-
Beth Israel Deaconess Medical CenterCompletedSialorrheaUnited States
-
Ospedale Generale Di Zona Moriggia-PelasciniUnknownRehabilitation | PD | Gait Dysfunction, NeurologicItaly
-
Lei LiRecruitingChemotherapy | Recurrent Cervical Carcinoma | Immune Checkpoint Inhibitors | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma | Albumin-bound PaclitaxelChina
-
Shanghai Ninth People's Hospital Affiliated to...Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Chest HospitalUnknownChemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaboratorsRecruitingNasopharyngeal Carcinoma | Surgery | PD-1China
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Università Politecnica delle MarcheNot yet recruitingLymphoma | Lung Neoplasms | Tuberculosis | EGF-R Positive Non-Small Cell Lung Cancer | Sarcoidosis | Mediastinal Lymphadenopathy | Hilar Lymphadenopathy | ROS1 Gene Mutation | PDL1 Gene Mutation | ALK TranslocationItaly
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyEnrolling by invitationKidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2) | Primary Hyperoxaluria Type 3 (PH3)United States, France, Germany, Japan, Lebanon, Spain, United Kingdom, Australia, Canada, Italy, Netherlands, Norway, Turkey
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruitingNasopharyngeal Carcinoma | Capecitabine | Radiotherapy | PD-1 InhibitorChina
-
Sichuan Cancer Hospital and Research InstituteActive, not recruitingNasopharyngeal Carcinoma | Chemoradiotherapy | PD-1 InhibitorsChina
-
Adamas Pharmaceuticals, Inc.CompletedParkinson's Disease (PD) | Dyskinesia | Levodopa Induced Dyskinesia (LID)France, Spain, United States, Canada, Germany, Austria
-
Shandong New Time Pharmaceutical Co., LTDNot yet recruitingNSCLC | Non-small Cell Lung Cancer | PD-1China
-
Shanghai Jiao Tong University School of MedicineRecruitingOral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFRChina
-
Sun Yat-sen UniversityCompletedBrain Metastases | NSCLC Stage IV | PD-1 AntibodyChina
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaboratorsNot yet recruitingCervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant ChemoimmunotherapyChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Tang-Du HospitalRecruitingChemotherapy | Esophageal Squamous Cell Carcinoma | PD-1 Inhibitor | NeoadjuventChina
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedPatients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment LinesItaly
-
Guangxi Medical UniversityWuzhou Red Cross Hospital; Wuhan Union Hospital, China; Yunnan Cancer Hospital; Hainan People's Hospital and other collaboratorsNot yet recruitingNasopharyngeal Carcinoma | Neoadjuvant Therapy | PD-1 Inhibitor
-
CuraSen Therapeutics, Inc.WithdrawnMild Cognitive Impairment (MCI) | Parkinson Disease (PD)
-
Sun Yat-sen UniversityRecruitingInduction Chemotherapy | Locally Advanced Nasopharyngeal Carcinoma | PD-L1 | EnvafolimabChina
-
RenJi HospitalRecruitingRadiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug ConjugatesChina
-
iPACES LLCAlbany Medical College; 1st Playable Productions; Pacific Brain Health Center; Adirondack... and other collaboratorsNot yet recruitingParkinson's Disease | Mild Cognitive Impairment | MCI | PDUnited States
-
Shanghai Jiao Tong University Affiliated Sixth...RecruitingCervical Cancer | Radiotherapy | Neoadjuvant Chemotherapy | PD-1 AntibodyChina
-
Spero TherapeuticsRecruitingNontuberculous Mycobacterial Pulmonary Disease (NTM-PD)United States
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaboratorsRecruitingNasopharyngeal Cancer | Chemotherapy | Radiotherapy | PD-1 TherapyChina
-
Oslo University HospitalActive, not recruiting
-
Escape Bio, Inc.Momentum Pharma; Science 37TerminatedPatients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) GeneUnited States
-
ACADIA Pharmaceuticals Inc.CompletedTreatment of Depression in Adults With Parkinson's Disease (PD)United States
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaboratorsRecruitingNasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | PD-1 TreatmentChina
-
Shirish GadgeelMerck Sharp & Dohme LLCWithdrawnNon Small Cell Lung Cancer | PD-L1 Gene Mutation | Advanced Lung Non-Small Cell Carcinoma
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingEsophageal Squamous Cell Carcinoma (ESCC) | PD-1 InhibitorsChina
-
Beijing Friendship HospitalNot yet recruitingLymphoma | Hemophagocytic Lymphohistiocytosis | PD-1 Antibody | Epstein-Barr VirusChina
-
Istituto Scientifico Romagnolo per lo Studio e...RecruitingProgressive Disease | Mesothelioma, Malignant | Advanced Cancer | PD-L1 NegativeItaly
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
iOMEDICO AGRoche Pharma AGCompletedExtensive-stage Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBCGermany
-
AstraZenecaPRA Health SciencesCompletedRecurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and NeckUnited States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
-
Second Affiliated Hospital, School of Medicine,...RecruitingOvarian Cancer | Neoadjuvant Chemotherapy | Anti-PD-1 | Neoadjuvant ImmunotherapyChina
-
AstraZenecaCompletedRecurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHNUnited States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
-
The Second Affiliated Hospital of Chongqing Medical...Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...Not yet recruitingChronic Hepatitis b | Anti-PD-1 Antibody | Peg-IFNαChina